70 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author김지은-
dc.date.accessioned2018-03-23T04:36:10Z-
dc.date.available2018-03-23T04:36:10Z-
dc.date.issued2014-10-
dc.identifier.citationCLINICAL MICROBIOLOGY AND INFECTION , Vol.20 No.10 [2014] , O721-O729en_US
dc.identifier.issn1198-743X-
dc.identifier.urihttp://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(14)65412-4/abstract-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/51183-
dc.description.abstractIn patients with community-onset acute pyelonephritis (CO-APN), assessing the risk factors for poor clinical response after 72h of antibiotic treatment (early clinical failure) is important. The objectives of this study were to define those risk factors, and to assess whether early clinical failure influences mortality and treatment outcomes. We prospectively collected the clinical and microbiological data of women with CO-APN in South Korea from March 2010 to February 2012. The numbers of cases in the early clinical success and early clinical failure groups were 840 (79.1%) and 222 (20.9%), respectively. Final clinical failure and mortality were higher in the early clinical failure group than in the early clinical success group (14.9% vs 2.3%, p<0.001; 6.8% vs 0.1%, p0.001, respectively). In a multiple logistic regression model, the risk factors for early clinical failure among the total 1062 patients were diabetes mellitus (OR 1.5; 95% CI 1.1-2.1), chronic liver diseases (OR 3.3; 95% CI 1.6-6.7), malignancy (OR 2.2; 95% CI 1.1-4.4), Pitt score 2 (OR 2.5; 95% CI 1.6-3.8), presence of azotaemia (OR 1.8; 95% CI 1.2-2.7), white blood cell count 20000/mm(3) (OR 2.5; 95% CI 1.6-4.0), serum C-reactive protein level 20mg/dL (OR 1.7; 95% CI 1.2-2.4), and history of antibiotic usage within the previous year (OR 1.5; 95% CI 1.1-2.2). Analysing the subgroup of 743 patients with CO-APN due to Enterobacteriaceae, fluoroquinolone resistance of the uropathogen was another factor associated with early clinical failure (OR 1.7; 95% CI 1.1-2.5). Simple variables of underlying diseases, previous antibiotic usage and initial laboratory test outcomes can be used to decide on the direction of treatment in CO-APN.en_US
dc.description.sponsorshipThis work was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (Grant No. A102065).en_US
dc.language.isootheren_US
dc.publisherWILEY-BLACKWELL, 111 RIVER ST, HOBOKEN 07030-5774, NJ USAen_US
dc.subjectacute pyelonephritisen_US
dc.subjectearly clinical failureen_US
dc.subjectrisk factoren_US
dc.subjectURINARY-TRACT-INFECTIONSen_US
dc.subjectACUTE UNCOMPLICATED PYELONEPHRITISen_US
dc.subjectESCHERICHIA-COLIen_US
dc.subjectRISK-FACTORSen_US
dc.subjectBACTEREMIAen_US
dc.subjectMORTALITYen_US
dc.subjectHOSPITALIZATIONen_US
dc.subjectADULTSen_US
dc.subjectIMPACTen_US
dc.titleClinical characteristics predicting early clinical failure after 72 h of antibiotic treatment in women with community-onset acute pyelonephritis: a prospective multicentre studyen_US
dc.typeArticleen_US
dc.relation.no10-
dc.relation.volume20-
dc.identifier.doi10.1111/1469-0691.12500-
dc.relation.page721-729-
dc.relation.journalCLINICAL MICROBIOLOGY AND INFECTION-
dc.contributor.googleauthorWie, S. H.-
dc.contributor.googleauthorKi, M.-
dc.contributor.googleauthorKim, J.-
dc.contributor.googleauthorCho, Y. K.-
dc.contributor.googleauthorLim, S. K.-
dc.contributor.googleauthorLee, J. S.-
dc.contributor.googleauthorKwon, K. T.-
dc.contributor.googleauthorLee, H.-
dc.contributor.googleauthorCheong, H. J.-
dc.contributor.googleauthorPark, D. W.-
dc.relation.code2014027419-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidquidam76-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE